Clinical trials: NSCLC Stage II
Lung Cancer
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung…
- Trial name
- NCT00063258
- Testing
- Tarceva (OSI-774), Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small Cell Lung
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
- Trial name
- NCT00281021
- Testing
- Erlotinib plus Digoxin
- Volunteers
- 26 people
- Sponsor
- University of Louisville
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01259089
- Testing
- erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Non-small Cell Lung Cancer
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the…
- Trial name
- NCT00567359
- Testing
- Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00424840
- Testing
- Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Advanced Non-small Cell Lung Cancer
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a non-randomized, single-arm, single-institution, open label, two-stage phase II and dose-ranging study designed to evaluate the efficacy and safety of paclitaxel poliglumex in combination with pemetrexed in patients with…
- Trial name
- NCT00487669
- Testing
- paclitaxel poliglumex, pemetrexed
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-small Cell Lung Cancer
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
The purpose of this study is to determine the efficacy and the toxicities of the study drug PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype retinoblastoma protein (RB) and inactivated…
- Trial name
- NCT01291017
- Testing
- PD0332991
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
The trial will be performed to evaluate whether BI 2536 may be effective in the treatment of advanced or metastatic NSCLC of stage IIIB or IV in patients who relapsed after or failed first-line therapy.
- Trial name
- NCT00376623
- Testing
- BI 2536
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
To determine the efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in previously treated NSCLC patients
- Trial name
- NCT02323126
- Testing
- EGF816, INC280, Nivolumab
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This randomized phase II trial studies how well erlotinib hydrochloride (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor…
- Conditions
- EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01532089
- Testing
- Bevacizumab, Erlotinib, Erlotinib Hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Academic and Community Cancer Research United
Lung Cancer
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00096226
- Testing
- Induction Carboplatin, Induction Paclitaxel, Resection
- Where
- 22 sites in United States
- Volunteers
- 60 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
- Trial name
- NCT00402883
- Testing
- Bevacizumab, Pemetrexed, Radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- SCRI Development Innovations, LLC
Non Small Cell Lung Cancer, EGFR Gene Mutation
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
This is an open-label, non-randomised, phase II, multi-centre clinical trial 26 patients will be enrolled in this trial to evaluate the major pathologic response in patients with neoadjuvant treatment with Carboplatin Pemetrexed…
- Trial name
- NCT04512430
- Testing
- Atezolizumab, Bevacizumab, Carboplatin
- Where
- 18 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Fundación GECP
NSCLC, Solid Tumors
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
Background: Carboplatin-paclitaxel is a commonly used chemotherapy combination for advanced non-small-cell lung carcinoma (NSCLC) and other solid tumors.
- Trial name
- NCT01100931
- Testing
- YM155, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Trial name
- NCT01737502
- Testing
- Auranofin, Sirolimus, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent…
- Conditions
- Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- NCT03916419
- Testing
- ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Non-small Cell Lung Cancer Stage IV
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM.
- Trial name
- ATEZO-BRAIN (NCT03526900)
- Testing
- Atezolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Lung Cancer Group
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC